UBS AM
CDNA icon

UBS AM’s CareDx CDNA Stock Holding History

UBS AM’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.14M Sell
110,031
-5,754
-5% -$125K ﹤0.01% 1856
2026
Q1 		$2.01M Sell
115,785
-9,405
-8% -$178K ﹤0.01% 2045
2025
Q4 		$2.36M Sell
125,190
-15,729
-11% -$263K ﹤0.01% 1824
2025
Q3 		$2.05M Sell
140,919
-133,769
-49% -$1.91M ﹤0.01% 1739
2025
Q2 		$5.37M Buy
274,688
+140,722
+105% +$2.5M ﹤0.01% 1674
2025
Q1 		$2.38M Buy
133,966
+13,619
+11% +$293K ﹤0.01% 1906
2024
Q4 		$2.58M Buy
120,347
+66,833
+125% +$1.63M ﹤0.01% 1919
2024
Q3 		$1.67M Buy
+53,514
New +$1.33M ﹤0.01% 2141
2023
Q4 		– Sell
-80,489
Closed -$563K – 2555
2023
Q3 		$563K Buy
80,489
+7,172
+10% +$66.3K ﹤0.01% 2252
2023
Q2 		$670K Hold
73,317
– – ﹤0.01% 2198
2023
Q1 		$670K Buy
73,317
+25,366
+53% +$324K ﹤0.01% 2198
2022
Q4 		$547K Sell
47,951
-2,735
-5% -$40.5K ﹤0.01% 2149
2022
Q3 		$863K Sell
50,686
-1,593
-3% -$34.2K ﹤0.01% 2056
2022
Q2 		$1.12M Sell
52,279
-11,545
-18% -$320K ﹤0.01% 1892
2022
Q1 		$2.36M Buy
63,824
+15,293
+32% +$596K ﹤0.01% 1722
2021
Q4 		$2.21M Sell
48,531
-238,241
-83% -$12.4M ﹤0.01% 1822
2021
Q3 		$18.2M Sell
286,772
-4,808
-2% -$366K 0.01% 897
2021
Q2 		$26.7M Sell
291,580
-13,530
-4% -$1.08M 0.01% 807
2021
Q1 		$20.8M Sell
305,110
-5,823
-2% -$452K 0.01% 853
2020
Q4 		$22.5M Sell
310,933
-84,931
-21% -$4.92M 0.01% 821
2020
Q3 		$15M Buy
395,864
+675
+0.2% +$22.8K 0.01% 844
2020
Q2 		$14M Buy
395,189
+366,311
+1,268% +$10.4M 0.01% 835
2020
Q1 		$630K Sell
28,878
-892
-3% -$20K ﹤0.01% 1885
2019
Q4 		$642K Sell
29,770
-4,057
-12% -$93.1K ﹤0.01% 2130
2019
Q3 		$765K Buy
33,827
+9,333
+38% +$258K ﹤0.01% 2081
2019
Q2 		$882K Buy
24,494
+3,200
+15% +$102K ﹤0.01% 1947
2019
Q1 		$671K Buy
21,294
+8,594
+68% +$250K ﹤0.01% 1985
2018
Q4 		$319K Buy
+12,700
New +$326K ﹤0.01% 2189

Other funds holding CDNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's CDNA Position: Q2 2026 in Review

UBS AM reduced its CareDx (CDNA) stake by 5% in Q2 2026, selling an estimated $125K and leaving 110,031 shares worth $3.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

UBS AM first reported a position in CDNA in Q4 2018 and has held it in 28 quarters since. The position peaked at $26.7M in Q2 2021. 227 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

  • UBS AM held 110,031 shares of CareDx worth $3.14M as of Q2 2026.
  • UBS AM sold 5,754 CareDx shares in Q2 2026, an estimated $125K.
  • CareDx made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1856 holding.
  • UBS AM first reported a position in CareDx in Q4 2018 and has held it in 28 quarters since.
  • UBS AM's CareDx position peaked at $26.7M in Q2 2021.
  • 227 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.